{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Oral", "query": { "intervention": "Placebo-Oral" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10195, "total_pages": 1020, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-Oral&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T18:56:15.530Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00724048", "title": "A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Huntington Disease" ], "interventions": [ { "name": "ACR16", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 227, "start_date": "2008-10-24", "completion_date": "2010-07-26", "has_results": true, "last_update_posted_date": "2023-08-31", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 22, "location_summary": "Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00724048" }, { "nct_id": "NCT01967940", "title": "Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections", "Acquired Immunodeficiency Syndrome" ], "interventions": [ { "name": "TAF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "Current failing ARV regimen", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2013-10-25", "completion_date": "2017-07-31", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 5, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Wilton Manors", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01967940" }, { "nct_id": "NCT03320018", "title": "Neuroprotection in Acute Ischemic Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Stroke, Ischemic" ], "interventions": [ { "name": "Hydrogen", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Placebo Hydrogen", "type": "OTHER" }, { "name": "Placebo Minocycline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-08-02", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03320018" }, { "nct_id": "NCT03068910", "title": "Hyperandrogenemia and Altered Day-night LH Pulse Patterns", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hyperandrogenism", "Polycystic Ovary Syndrome", "Puberty" ], "interventions": [ { "name": "Micronized progesterone", "type": "DRUG" }, { "name": "Spironolactone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "FEMALE", "summary": "10 Years to 17 Years · Female only" }, "enrollment_count": 32, "start_date": "2016-07-21", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068910" }, { "nct_id": "NCT01395914", "title": "Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cachexia", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Anamorelin HCl", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Therapeutics (U.S.), Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 513, "start_date": "2011-07", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-09-14", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 19, "location_summary": "Corona, California • Fountain Valley, California • Fullerton, California + 16 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01395914" }, { "nct_id": "NCT01147458", "title": "A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis, Knee" ], "interventions": [ { "name": "PF-04191834", "type": "DRUG" }, { "name": "PF-04191834 placebo", "type": "DRUG" }, { "name": "Naproxen placebo", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 190, "start_date": "2010-07", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2013-06-06", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 25, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147458" }, { "nct_id": "NCT03030248", "title": "Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection", "Hematologic Diseases", "Bone Marrow Transplant", "Oncologic Disorders" ], "interventions": [ { "name": "Vancomycin Oral Capsule", "type": "DRUG" }, { "name": "Placebo Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-06-01", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030248" }, { "nct_id": "NCT00890890", "title": "A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Avagacestat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "45 Years to 90 Years" }, "enrollment_count": 263, "start_date": "2009-05", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890890" }, { "nct_id": "NCT01898884", "title": "Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Friedreich's Ataxia" ], "interventions": [ { "name": "VP 20629", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 46, "start_date": "2013-08-13", "completion_date": "2015-06-18", "has_results": true, "last_update_posted_date": "2021-06-02", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 5, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01898884" }, { "nct_id": "NCT06854952", "title": "A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overweight or Obesity" ], "interventions": [ { "name": "TERN-601", "type": "DRUG" }, { "name": "Matching Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 167, "start_date": "2025-03-07", "completion_date": "2025-09-19", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-12T18:56:15.530Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Spring Valley", "state": "California" }, { "city": "Port Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06854952" } ] }